AKT1 and cancer: Although several PI3K/Akt inhibitors have been clinically developed for cancer therapy, therapeutic applications of these agents are limited at least in part by their extensive effects on cellular metabolism that cause off-target impacts, such as hyperglycemia, hyperinsulinemia, and reactivation of PI3K as a consequence [167].